logo-loader
viewInstem PLC

Instem PLC's Phil Reason says they've been really busy during lockdown and welcomes new Korea deal

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy' during the lockdown period as the majority of their revenue comes from clients whose laboratories are regarded as "essential businesses" with many working on COVID-19 related vaccines and therapies.

Quick facts: Instem PLC

Price: 455 GBX

AIM:INS
Market: AIM
Market Cap: £93.19 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tech in focus: Instem, Alfa Financial Software and Attraqt

Proactive analyst Richard Jeans takes a look at the UK tech industry and picks three stocks he has been watching this week. Jeans firstly focuses on Instem (LON:INS) which is a software business servicing the global life sciences market, which recently reported a 12% organic growth rate for...

3 weeks ago

2 min read